Sugi Predict

Sugi Predict / Compounds / SCHEMBL374867

SCHEMBL374867

SCHEMBL374867

CC[C@@H](C=O)NC(=O)OC(C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 19/20 0.66
▸ CTSS P25774 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1802737 1.00 CTSK (0.66) CTSKCTSSCA1CA2CA7
SCHEMBL12538274 1.00 CTSK (0.66) CTSKCTSSCA1CA2CA7
SCHEMBL29957942 0.86 CTSK (0.59) CTSKCTSSCA1CA2CA7
SCHEMBL418758 0.86 CTSK (0.63) CTSK
SCHEMBL12635080 0.86 CTSK (0.63) CTSK
SCHEMBL3667036 0.86 CTSK (0.63) CTSK
SCHEMBL2405499 0.85 CTSK (0.66) CTSKCA1CA2CA7
SCHEMBL3212396 0.85 CTSK (0.66) CTSKCA1CA2CA7
SCHEMBL5488672 0.84 CTSK (0.50) CTSKCTSS
SCHEMBL23279488 0.84 CTSK (0.64) CTSKCA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060229343-A1 Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) 2006-10-12 — — US claimed
US-7115639-B2 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-10-03 — — US claimed
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives MERCK SERONO SA (CH) 2004-11-04 — — US claimed
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K VIVIDION THERAPEUTICS, INC. 2025-01-23 — — US disclosed
EP-4469448-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2024-12-04 — — EP disclosed
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 — — US disclosed
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2024-06-20 — — US disclosed
EP-4338737-A1 PARP7 INHIBITOR AND USE THEREOF Novostar Pharmaceuticals, Ltd. (CN) 2024-03-20 — — EP disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
EP-0932617-B1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE VERTEX PHARMA (US) 2002-01-16 — — EP disclosed
EP-1136498-A1 Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease Vertex Pharmaceuticals Incorporated (US) 2001-09-26 — — EP disclosed
US-6265380-B1 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease VERTEX PHARMACEUTICALS INCORPORATED 2001-07-24 — — US disclosed
EP-1066247-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE Vertex Pharmaceuticals Incorporated (US) 2001-01-10 — — EP disclosed
CN-1238780-A Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease VERTEX PHARMA (US) 1999-12-15 — — CN disclosed
WO-1999050230-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-10-07 — — WO disclosed
EP-0932617-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE Vertex Pharmaceuticals Incorporated (US) 1999-08-04 — — EP disclosed
WO-1999012912-A1 THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH YUHAN CORPORATION (KR) 1999-03-18 — — WO disclosed
WO-1998017679-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K KRAS, HRAS, NRAS CTSK 1313/4885CTSS 1010/4885CA1 4347/4885
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives OXTR, PRLHR, PGF CTSK 4097/4885CTSS 4679/4885CA1 4729/4885
US-20060229343-A1 Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists OXTR, PRLHR, OXER1 CTSK 4276/4885CTSS 4756/4885CA1 4588/4885
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 CTSK 2259/4885CTSS 2429/4885CA1 3814/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 CTSK 2511/4885CTSS 3101/4885CA1 4498/4885
US-20230365529-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 CTSK 2511/4885CTSS 3101/4885CA1 4498/4885
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 CTSK 908/4885CTSS 4282/4885CA1 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.